@BioCentury profile picture
BioCentury @BioCentury

The leading voice for decision-makers throughout the global biopharma ecosystem. Follow us on LinkedIn for exclusive insights & analysis: bit.ly/4b1HDDu

Joined December 2010
  • Tweets 39,497
  • Following 1,798
  • Followers 16,710
885 Photos and videos
In BioCentury's latest Management Tracks: New CEOs at Dualitas, Apnimed, Vergent and Oriva; Ambros taps Regulus veterans; a new leader at the U.K.'s BIA; and more buff.ly/fCBGkq6

New CEOs at Dualitas, Apnimed, Vergent and Oriva: Management Tracks

A long list of biotech companies introduced new CEOs in recent days, including private companies Dualitas Therapeutics Inc., Apnimed Inc., Vergent Biosc...

biocentury.com
2
2
377
WuXi AppTec filed suit contesting designation as Chinese military co., cites harms beyond Biosecure buff.ly/SSae9Pp

WuXi AppTec contests military designation

WuXi AppTec is contesting its designation as a Chinese military company and, in the process, has detailed a range of harms it says flow from the designatio...

biocentury.com
1
1
332
Houston’s biopharma story is shifting from institutional scale to translational connectivity buff.ly/hhvSGlL

Houston’s translational moment looks beyond its clinical prowess

Houston has long been recognized for its scale. Now it’s biotech’s turn to be the beneficiary. Anchored by the world’s largest medical...

biocentury.com
1
315
With the upgrade to the Innovation Distillery, BioCentury is expanding its horizon-scanning tools, data and analysis to help drug hunters track where translational science is heading next buff.ly/k2FaRXh

The horizon just got closer: Letter from the Editor

The best thing about this job, I’ve often said, is that it never gets old. There’s never an end to new discoveries, and it’s always sp...

biocentury.com
3
307
In BioCentury's Public Equity Report: Parabilis' underwriters top off its offering as Kardigan outlines its IPO ambitions; plus follow-ons for Tango, Enliven, and more buff.ly/1N2Wkx0

Parabilis completes $770M IPO as Kardigan lines up in queue: Public Equity Report

While the enormous offering by Space Exploration Technologies Corp. (NASDAQ:SPCX) grabbed headlines this week, investors still poured plenty of cash i...

biocentury.com
2
390
GDF15 emerges as cachexia's lead target, with Pfizer and CatalYm in Phase II/III. The cytokine sits at the intersection of tumor immune evasion and muscle wasting, offering drug developers a rare chance to address both at once buff.ly/SSqKRSL

GDF15 emerges as cachexia’s lead target, with Pfizer and CatalYm in Phase II/III

For the first time, cancer-associated cachexia — a wasting syndrome that drives a substantial share of cancer deaths and has no approved treatments ...

biocentury.com
1
3
356
It’s about time: How the political calendar will shape biopharma’s future. Elections and legislative deadlines will likely keep Kennedy in place through November, slow FDA leadership changes, and set the pace for FDA reform buff.ly/1aNrugH

It’s about time: How the political calendar will shape biopharma’s future

Biopharma public policy experts have struggled to keep up with the twists and turns of 2026. The year isn’t quite half over, and while there’...

biocentury.com
1
2
550
In BioCentury's Venture Report: Ethyreal launches with a long-acting anti-TSHR program that could compete in thyroid eye disease and Graves disease; plus fundings for Beren, City, and more buff.ly/WDYRIgq

Ethyreal launches with $101M, aiming to compete in Tepezza’s arena: Venture Report

Newly launched Ethyreal revealed this week that it has raised $101 million across two venture rounds that will drive its long-acting therapy for Grave...

biocentury.com
1
4
486
The combination of GHO Capital and CBC Group creates a global #healthcare investor that can invest broadly across healthcare sectors and geographies with a combined $21B AUM buff.ly/h76TOLC

Two healthcare investors go global together

The merger of GHO Capital and CBC Group could function as a template for firms aiming to build a global investment platform with synergies across both regi...

biocentury.com
1
2
408
Building a biomarker stack to stratify Alzheimer’s trials. BioCentury’s revamped Innovation Distillery provides insight into new Alzheimer’s biomarkers buff.ly/wds2fOK

Building a biomarker stack to stratify Alzheimer’s trials

A run of recent studies is pushing neurodegeneration biomarkers past the binary question of whether pathology is present toward a layered set of plasma and...

biocentury.com
1
4
326
Pinnacle is tackling oral peptides' longstanding bioavailability problem with a design-first platform and a team that has done it before. Biotech will take an oral peptide for COPD into the clinic by year-end, backed by an $89M series B announced in March buff.ly/drC0hAc

Pinnacle: Designing oral peptides to close the gap with injectable biologics

Pinnacle is tackling oral peptides’ longstanding bioavailability problem with a design-first platform and a team that has done it before.Historicall...

biocentury.com
2
3
529
Moving faster at the academia-industry interface — a BioCentury podcast from Grand Rounds U.S. - Seattle. Hosted by @biopharmajosh buff.ly/RlDuVKy

Moving faster at the academia-industry interface — a BioCentury podcast

Getting into the clinic fast to de-risk assets has become the name of the game in biotech, and at the academia-industry interface, too. From AI to NAMs to ...

biocentury.com
3
369
LRRK2 inhibitor failure pushes Parkinson's field toward genetic enrichment. With Biogen and Denali's BIIB122 missing in Parkinson's all-comers, the question may no longer be whether to enrich trial populations, but how. buff.ly/sxQTlC9

LRRK2 inhibitor failure pushes Parkinson's field toward genetic enrichment

For years, researchers hoped that LRRK2 — a target rooted in Parkinson's genetics — might benefit patients broadly, even those without t...

biocentury.com
1
5
415
Parabilis raised $670M in an IPO that priced late Tuesday, as well as $75M in a concurrent placement -- but the total size of its offering could still rise even higher buff.ly/McOudup

Where Parabilis’ massive IPO ranks among biotech debuts on NASDAQ

With a first-day share price gain of 58% on Wednesday, Parabilis is likely to have the largest NASDAQ IPO in history by a pure-play biopharma, if its under...

biocentury.com
6
15,608
The race to create a new Ebola vaccine. @CEPIvaccines' $60M funding commitment aims to advance Bundibugyo virus vaccines to the clinic as fast as possible. buff.ly/r7DTAQS

The race for a vaccine against rare Ebola virus

As an Ebola outbreak caused by Bundibugyo virus grows, the Coalition for Epidemic Preparedness Innovations is committing more than $60 million to acce...

biocentury.com
4
499
In the third and largest acquisition of Luke Miels' brief tenure thus far as CEO, GSK is buying Nuvalent for $10.6B to gain two registration-stage therapies for targeted groups of lung cancer patients buff.ly/JBTzmVG

In third deal under Miels, GSK adds targeted cancer therapies via $10.6B Nuvalent buy

GSK’s $10.6 billion acquisition of Nuvalent, its third and largest M&A transaction since Luke Miels became CEO this year, will give the pha...

biocentury.com
5
675
WuXi AppTec's listing as Chinese military company focuses attention Biosecure, additional measures aimed at reducing U.S. biopharmas' engagement with China. buff.ly/OG2nJqc

Impact of Biosecure starting to come into focus

The U.S. government’s decision to brand WuXi AppTec a Chinese military company signals that the Trump administration intends to treat life sciences ...

biocentury.com
1
1
484
The latest #BioCenturyThisWeek podcast out now: New leaders set tone at @US_FDA; billion-dollar deals by @Servier, @Incyte, J&J pace biopharma BD. @JNJnews. This week with @SteveUsdin1 @FishburnSimone @StephenPHansen @Jeff_Cranmer. buff.ly/RvrPSnh

Calmer waters for FDA; Servier, Lilly deals — a BioCentury podcast

FDA’s new leadership is sailing the agency into calmer waters amid a search for a permanent commissioner and permanent center directors. On the late...

biocentury.com
1
2
466
Eli Lilly dealmaking spree this year has seen it commit over $45B across 20 deals, with the majority of the capital directed at #autoimmune and #cancer deals, and only one focused on #obesity, and the majority of deals in research/preclinical stage $LLY buff.ly/a2R9dO4

Sizing up Lilly’s dealmaking spree

While most pharmas have been searching for commercial or late-stage assets to plug near-term LOE holes, the world’s most valuable biopharma company ...

biocentury.com
1
2
7
1,344
BioCentury's Deals Report features a pair of deals around protein degradation, as J&J buys Firefly and Roche works with Nurix buff.ly/BThSnts

J&J/Firefly, Roche/Nurix each strike degrader deals: Deals Report

J&J’s $1 billion deal for privately held Firefly is the biggest commitment yet by a pharma buyer in the emerging field of degrader-antibody...

biocentury.com
1
3
525
Load more